Production of Macrophage Migration Inhibitory Factor by Human and Murine NeuroblastomaBin Q. · Johnson B.D. · Schauer D.W. · Casper J.T. · Orentas R.J.
Department of Pediatrics, Section of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisc., USA
Tumor cells avoid immune recognition by subverting the ability of the immune system to mount an inflammatory response that generates cytotoxic effector cells. This can be achieved through cytokine production by the tumor itself. Our objective was to determine the cytokine profile of neuroblastoma (NB) lesions in tumor vaccine models. We found that the murine NB cell line, Neuro2a, secretes macrophage migration inhibitory factor, MIF, a multifunctional cytokine with the potential to block effective immune responses to a tumor. Patient-derived NB cell lines were also found to produce MIF. MIF production by NB was documented at the level of RNA by RNAse protection, soluble cytokine production by ELISA, and in a macrophage migration assay. Our studies also confirmed reports of IL-6 production by human NB cell lines. NB culture-derived MIF was also shown to activate tumor cell migration. This supports the hypothesis that MIF is a tumor-derived cytokine that may play a role in NB aggressiveness and evasion of immune recognition.
© 2002 S. Karger AG, Basel
Received: Received: December 14, 2001
Accepted after revision: May 14, 2002
Number of Print Pages : 7
Number of Figures : 4, Number of Tables : 0, Number of References : 41
Tumor Biology (Tumor Markers and Translational Cancer Research)
Founded 1980 as ‘Oncodevelopmental Biology and Medicine’ by the ISOBM, continued 1984–1986 as ‘Tumour Biology’
The Journal of the International Society for Oncodevelopmental Biology and Medicine (ISOBM)
Vol. 23, No. 3, Year 2002 (Cover Date: May-June 2002 (Released September 2002))
Journal Editor: T. Stigbrand, Umeå; Managing Editor: P.D. Rye, Oslo
ISSN: 1010–4283 (print), 1423–0380 (Online)
For additional information: http://www.karger.com/journals/tbi